Martin Dahl, Ph.D.
Vice President, Cell Biology
Martin Dahl, Ph.D. joined AnaptysBio in 2018 and has more than 25 years of experience in drug discovery and research. Prior to AnaptysBio, Martin was Global Head, Immunology Network at Takeda Pharmaceuticals, where he led immunology programs applicable to gastro-intestinal diseases, immuno-oncology, neuroinflammation, autoimmunity, and respiratory illnesses. Martin’s experience at Takeda included the development of various novel biologic modalities, including antibodies, T-cell engagers and cell therapy. Prior to Takeda, Martin was a group leader at Roche Pharmaceuticals, where he led research and preclinical programs in inflammation, autoimmunity and transplantation. Martin earned his Bachelor of Science degree at The University of California, Irvine, and his Ph.D. degree at Tokyo University, where we studied under one of the foremost experts in cytokine biology, Ken-Ichi Arai. Martin completed his postdoctoral training at Stanford University in the Department of Pediatrics, where he studied the roles of pulmonary dendritic cells and T cells in respiratory viral infections and how they contribute to chronic airway diseases such as asthma.